Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Open-Label Study of Tipifarnib in Advanced HRAS-Mutant Solid Tumors
2015-004535-12Phase 2Completed
- Sponsor
- Kura Oncology
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in Nonhematologic neoplasms, sponsored by Kura Oncology. Primary endpoint: Objective response rate (ORR) per RECIST 1.1. Started Jan 2016; status: completed.
02
Drugs
tipifarnib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2015-004535-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004535-12.